Messenger RNAs (mRNAs) represent a fast-emerging class of biotherapeutics. They hold considerable promise, offering new opportunities for targeted treatment and flexible manufacturing, as demonstrated by the rapid development of mRNA-based COVID-19 vaccines [1,2]. However, the field is still in its infancy, and the clinical potential of mRNA extends beyond vaccines. To date, there have been more than 330 clinical studies [3] involving mRNA as an active ingredient. Lonza has built considerable expertise in the production of mRNA, as both drug substance (DS) and drug product (DP) [4,5].

In this poster, we highlight mRNA production technology aspects, in particularly when considering commercial production and the validation of processes in a cGMP environment.

Additional Authors:

  • Michal Domański, MSAT Lead mRNA Development
  • Telmo Graça, Head of mRNA Process Development
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center